### Analysis

The Johnson & Johnson earnings call provided a detailed overview of the company's performance in 2015 and guidance for 2016. Key points include:

1. **2015 Performance**:
   - **Sales**: $70.1 billion, down 5.7% year-over-year (YoY).
   - **Operational Growth**: 1.8% YoY, excluding the impact of acquisitions and divestitures.
   - **Earnings**: $15.4 billion, up 4.8% YoY.
   - **EPS**: $5.48, up 3% YoY.

2. **2016 Guidance**:
   - **Sales**: $71.9 billion to $72.6 billion, up 2.5% to 3.5% YoY.
   - **EPS**: $6.53 to $6.68, up 5% to 8% YoY.

3. **Segment Performance**:
   - **Pharmaceuticals**: Strong growth in 2015, expected to continue in 2016.
   - **Consumer**: Improved margins and growth expected in 2016.
   - **Medical Devices**: 5.8% growth in 2015, expected to accelerate in 2016.

4. **Cost Management and M&A**:
   - **Margin Expansion**: 200 basis points expansion in 2016.
   - **M&A**: Focus on strategic acquisitions and partnerships to drive growth.

5. **Market Environment**:
   - **Healthcare**: Continued focus on innovation and value-based care.
   - **China**: Optimistic about growth in 2016.

### Conclusion

Johnson & Johnson's 2015 results were strong, with operational growth and earnings exceeding expectations. The company's guidance for 2016 is also positive, with expectations for sales and EPS growth. The focus on innovation, cost management, and strategic M&A positions the company well for continued growth. The market environment, including healthcare trends and the evolving role of technology, is favorable for the company's growth strategy.

### Rating

**1**